|
Showing 1 - 4 of
4 matches in All Departments
As the most common health-care intervention, prescription drug use
shares the most important characteristics of the health-care system
in the United States. When everything works well, it makes possible
breathtakingly successful applications of science to the prevention
and cure of human suffering. But everything doesn't always work
well. Pharmaceutical Public Policy provides the understanding and
framework required for effective organization, financing, and
delivery of pharmaceutical products and services. It supplies an
overview of the policy process as well as the roles of legislation
and regulation in pharmaceutical policy. The book identifies the
goals, objectives, and key policy issues of concern to stakeholders
involved in the development of products, use of pharmaceuticals in
healthcare, and administration of insurance programs by both the
private and government sectors. Policy issues examined include the
appropriateness of prescribing and patient adherence. Addressing
questions of access, quality, and cost, the book considers the
operation of the Affordable Care Act and Medicare Part D. It
details the responsibilities of Federal providers of pharmaceutical
care and private and public payers such as managed care
organizations, pharmacy benefit managers, Medicare, and Medicaid.
The book covers the policies and practices involved in promoting
pharmaceutical products. It also considers pharmacoeconomics as a
response to market failure. Finally, the book describes the market,
the role of the manufacturer, drug shortages, and the
responsibilities of the FDA. The book includes a Foreword by Jerry
Avorn, MD, Professor of Medicine, Harvard Medical School; and
Chief, Division of Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Woman's Hospital.
The effects of obesity have become practically ubiquitous in the
US. This book aims to provide an alternative framework through
which to explore the important and controversial obesity debate
that has spilled over from the medical community. This book is not
about obesity as a medical condition, nor does it offer a
wide-ranging discussion on the health effects of obesity or the
role of the 'right' diet. To this end, the contributors present a
multidisciplinary portrait of this complex problem. They explore
the rising trend in obesity of the US in terms of its significant
economic and social consequences. The web of underlying causes of
the 'infrastructure of obesity', they explain, lies with public
policy decisions, economic factors and profit opportunities as well
as the more obvious nutrition and health choices of individuals.
Prevention and treatment of this now global pandemic are then
tackled from the perspectives of businesses, governments, society
and the individual. The taxation, marketing, cultural, ethical and
institutional dimensions of obesity are also addressed. Obesity,
Business and Public Policy is unique in its broad social science
approach, exploring the obesity epidemic from economic, business,
legal, social and public policy perspectives. As such, this truly
multidisciplinary study will make fascinating reading for academics
and professionals from a wide variety of backgrounds including:
business, economics, public and social policy, medicine and
nutrition.
As the most common health-care intervention, prescription drug use
shares the most important characteristics of the health-care system
in the United States. When everything works well, it makes possible
breathtakingly successful applications of science to the prevention
and cure of human suffering. But everything doesn't always work
well. Pharmaceutical Public Policy provides the understanding and
framework required for effective organization, financing, and
delivery of pharmaceutical products and services. It supplies an
overview of the policy process as well as the roles of legislation
and regulation in pharmaceutical policy. The book identifies the
goals, objectives, and key policy issues of concern to stakeholders
involved in the development of products, use of pharmaceuticals in
healthcare, and administration of insurance programs by both the
private and government sectors. Policy issues examined include the
appropriateness of prescribing and patient adherence. Addressing
questions of access, quality, and cost, the book considers the
operation of the Affordable Care Act and Medicare Part D. It
details the responsibilities of Federal providers of pharmaceutical
care and private and public payers such as managed care
organizations, pharmacy benefit managers, Medicare, and Medicaid.
The book covers the policies and practices involved in promoting
pharmaceutical products. It also considers pharmacoeconomics as a
response to market failure. Finally, the book describes the market,
the role of the manufacturer, drug shortages, and the
responsibilities of the FDA. The book includes a Foreword by Jerry
Avorn, MD, Professor of Medicine, Harvard Medical School; and
Chief, Division of Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Woman's Hospital.
The effects of obesity have become practically ubiquitous in the
US. This book aims to provide an alternative framework through
which to explore the important and controversial obesity debate
that has spilled over from the medical community. This book is not
about obesity as a medical condition, nor does it offer a
wide-ranging discussion on the health effects of obesity or the
role of the 'right' diet. To this end, the contributors present a
multidisciplinary portrait of this complex problem. They explore
the rising trend in obesity of the US in terms of its significant
economic and social consequences. The web of underlying causes of
the 'infrastructure of obesity', they explain, lies with public
policy decisions, economic factors and profit opportunities as well
as the more obvious nutrition and health choices of individuals.
Prevention and treatment of this now global pandemic are then
tackled from the perspectives of businesses, governments, society
and the individual. The taxation, marketing, cultural, ethical and
institutional dimensions of obesity are also addressed. Obesity,
Business and Public Policy is unique in its broad social science
approach, exploring the obesity epidemic from economic, business,
legal, social and public policy perspectives. As such, this truly
multidisciplinary study will make fascinating reading for academics
and professionals from a wide variety of backgrounds including:
business, economics, public and social policy, medicine and
nutrition.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Ab Wheel
R209
R149
Discovery Miles 1 490
Tenet
John David Washington, Robert Pattinson, …
DVD
R53
Discovery Miles 530
|